Ciprian T.
- Country
- Romania
- Department
- Secția Clinica Hematologie
Research Overview
- Phase 1 Dose-Determining Study of EXS73565 in Patients with Relapsed or Refractory B-Cell Malignancies Including CLL, MCL, DLBCL, FL, and MZL
- Phase 3 Randomized Open‑Label Study of Elritercept Versus Epoetin Alfa for Anemia in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndromes Requiring RBC Transfusions
- Phase 1b/2 Evaluation of BMS-986158 Alone and with Ruxolitinib or Fedratinib in DIPSS-Intermediate/High Risk Myelofibrosis Patients
Data & Insights
Has run more than one trial at 131 of 317 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating acute myeloid leukemia (AML), with particular focus on addressing refractory and relapsed cases. Their research interest centers on developing innovative therapeutic approaches for patients who require second-line treatment options.
- Refractory/Relapsed AML Management
- Combination Therapy Approaches
- Treatment Response Assessment
The investigator's work encompasses evaluating novel therapeutic combinations to enhance treatment outcomes in challenging hematologic conditions.
Clinical Innovation
The investigator focuses on advancing remission induction strategies through the evaluation of novel drug combinations. Their expertise includes determining optimal dosing regimens for innovative therapeutic agents in hematologic malignancies.
- Drug Optimization Studies
- Remission Rate Assessment
- Treatment Protocol Development
Their research contributes to establishing more effective treatment protocols for patients with resistant forms of blood cancers.
Therapeutic Development
The investigator's work involves comparative therapeutic studies in hematologic oncology, with emphasis on evaluating novel agents against established treatments. They focus on developing enhanced treatment options for patients with limited therapeutic alternatives.
- Second-line Therapy Development
- Treatment Response Evaluation
- Clinical Efficacy Assessment
Their research aims to expand the therapeutic arsenal available for treating resistant forms of leukemia.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.